VolitionRx Limited, a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases in both humans and animals, has announced the launch of its first product, the Nu.Q™ Vet Cancer Screening Test.
Austin, Texas, Dec. 1, 2020 – The test, which as of yesterday is available to order by veterinarians in the U.S. from the GI Lab at Texas A&M University, is positioned for use in the annual wellness check of older dogs or for cases where there is a suspicion of cancer. It can also be a complementary test for younger dogs of breeds with a high risk for developing cancer in their lifetimes, such as Golden Retrievers. The potential market opportunity is significant given that there are approximately 77 million dogs in the U.S. Volition expects its initial revenue to be $45 per test.
During this initial launch phase, Volition is focused on driving awareness of the test not only across the specialist oncology community nationwide but also the general practice veterinarians in Texas (our chosen Beta market) through a series of “lunch and learns”, product mailings, a social media campaign and a Webinar featuring Professor. Heather Wilson-Robles and Dr. Sue Ettinger (aka Dr. Sue Cancer Vet).
Commenting on the launch, Cameron Reynolds, Chief Executive Officer of Volition said, “The launch of the Nu.Q™ Vet Cancer Screening Test is a stand out moment in our ten year history and an extremely important milestone for our company. It demonstrates that our Nu.Q™ platform has now attained both the reliability and reproducibility to launch in an independent laboratory. After setting up our veterinary subsidiary just over a year ago, the combination of experience and expertise of the Volition Veterinary and Texas A&M teams has enabled this incredible speed to market, especially considering the pandemic. This is a hugely important test that we hope will fundamentally change how veterinarians manage cancer detection in dogs.”
Professor Heather Wilson-Robles of Texas A&M University and Chief Medical Officer of Volition Veterinary Diagnostics Development LLC said, “Unlike in humans, where routine cancer screening is relatively commonplace, there are few tests for animals. We are changing this today, with the launch of the Nu.Q™ Vet Cancer Screening Test. This simple, low-cost blood test can help streamline the diagnostic process and shorten the path to diagnosis thereby allowing treatment (be that therapy or surgery) to be initiated earlier, even before symptoms appear, increasing the chance of the dog’s survival and its quality of life. I am so looking forward to speaking to as many key opinion leaders and veterinarians themselves over the coming months to let them know about this fantastic new way to help dogs be diagnosed and treated.”
Volition is a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases. Early diagnosis has the potential to not only prolong the life of patients, but also to improve their quality of life. The tests are based on the science of NucleosomicsTM, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid – an indication that disease is present. Volition is primarily focused on human diagnostics but also has a subsidiary focused on animal diagnostics.
Volition’s research and development activities are centered in Belgium, with a small laboratory in California and additional offices in Texas, London and Singapore, as the company focuses on bringing its diagnostic products to market. For more information about Volition, visit Volition’s website volition.com.